Jinxin Fertility Group Limited (JXR) disclosed that it repurchased 1.24 million ordinary shares on 15 May 2026 via on-market transactions at a uniform price of HKD 2.38 per share, for a total consideration of HKD 2.96 million.

The latest transaction lifts the cumulative number of shares bought back under the current mandate, granted on 26 June 2025, to 70.41 million—equivalent to 2.57 % of the company’s issued share capital on the mandate date.

As at the close of 15 May 2026, JXR’s issued share capital remains at 2.71 billion shares. Of these, 30.75 million shares (1.14 % of the current issued base) have been repurchased but are still pending formal cancellation.

The repurchase window triggers a 30-day moratorium on new share issues, sales, or transfers, restricting such activities until 14 June 2026, in line with Hong Kong listing rules. All repurchases were conducted in accordance with the Main Board regulations, and the company reports no changes to the explanatory statement filed on 4 June 2025.